Aerie pharmaceuticals, inc. (nasdaqgm:aeri) entered into an agreement to acquire avizorex pharma,sl from inveready innvierte biotech ii, scr, s.a. managed by inveready asset management, s.g.e.i.c., s.a. for $10 million.

Aerie pharmaceuticals, inc. (nasdaqgm:aeri) entered into an agreement to acquire avizorex pharma,sl from inveready innvierte biotech ii, scr, s.a. managed by inveready asset management, s.g.e.i.c., s.a. for $10 million on november 18, 2019. under the terms of the agreement, aerie will acquire avizorex in an all-cash transaction. aerie will make an upfront payment of $10 million, subject to customary adjustments and avizorex shareholders will be eligible to receive additional payments subject to achievement of certain clinical and regulatory performance milestones, plus royalties on net sales of approved products from avizorex’s development pipeline. the transaction is expected to close before the end of the year 2019.
AERI Ratings Summary
AERI Quant Ranking